Lineage Cell Therapeutics (NYSEAMERICAN:LCTX – Get Free Report) will likely be releasing its Q3 2026 results after the market closes on Thursday, November 5th. Analysts expect Lineage Cell Therapeutics to post earnings of ($0.02) per share and revenue of $2.32 million for the quarter. Parties can check the company’s upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Thursday, November 12, 2026 at 4:30 PM ET.
Lineage Cell Therapeutics (NYSEAMERICAN:LCTX – Get Free Report) last released its quarterly earnings data on Thursday, August 6th. The company reported ($0.03) earnings per share for the quarter, hitting the consensus estimate of ($0.03). The business had revenue of $1.07 million during the quarter, compared to analysts’ expectations of $1.84 million. Lineage Cell Therapeutics had a negative return on equity of 73.06% and a negative net margin of 246.58%. On average, analysts expect Lineage Cell Therapeutics to post ($0.07) EPS for the current fiscal year and ($0.04) EPS for the next fiscal year.
Lineage Cell Therapeutics Stock Performance
Shares of Lineage Cell Therapeutics stock opened at $1.01 on Tuesday. The business has a 50 day moving average of $1.01 and a 200 day moving average of $1.33. Lineage Cell Therapeutics has a 52 week low of $0.88 and a 52 week high of $2.09.
Wall Street Analysts Forecast Growth
Separately, HC Wainwright reiterated a “buy” rating on shares of Lineage Cell Therapeutics in a report on Tuesday, July 14th. Four investment analysts have rated the stock with a Buy rating. According to MarketBeat.com, Lineage Cell Therapeutics currently has an average rating of “Buy” and a consensus price target of $6.25.
Read Our Latest Report on Lineage Cell Therapeutics
Lineage Cell Therapeutics Company Profile
Lineage Cell Therapeutics, Inc is a biotechnology company focused on developing allogeneic cell therapies for unmet medical needs. The company uses its proprietary cell differentiation and manufacturing technologies to create specialized human cells intended to replace, repair or support damaged tissues.
Lineage’s lead program, OpRegen, is an investigational retinal pigment epithelium cell replacement therapy being developed for geographic atrophy, an advanced form of dry age-related macular degeneration.
Read More
- Five stocks we like better than Lineage Cell Therapeutics
- SpaceX Sent Verizon and T-Mobile Stocks Tumbling—Did Wall Street Overreact?
- SpaceX Starlink’s Telecom Ground Game Takes Shape
- AST SpaceMobile’s Brazil Breakthrough Could Set the Stage for a Q3 Stock Rebound
- AbbVie’s Humira Era Is Fading, But Its New Growth Engines Face Another Test
Receive News & Ratings for Lineage Cell Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lineage Cell Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
